Related Experiment Videos
Prostacyclin aerosol in an infant with pulmonary hypertension
B Santak1, M Schreiber, P Kuen
1Universitätsklinik für Anästhesiologie, Klinikum der Universität, Ulm, Germany.
Insights
Aerosolized prostacyclin selectively dilated pulmonary arteries in an infant with idiopathic pulmonary hypertension. This treatment improved cardiac function and may be a safe alternative to inhaled nitric oxide.
Area of Science:
- Pediatric Cardiology
- Pulmonology
- Pharmacology
Background:
- Idiopathic pulmonary hypertension (IPH) in infants presents significant challenges.
- Current treatments for IPH have limitations and potential toxicities.
Observation:
- Aerosolized prostacyclin (100 ng/kg.min) was administered to an infant with IPH.
- Hemodynamic parameters were monitored to assess treatment effects.
Findings:
- Selective pulmonary vasodilation was observed without systemic hypotension.
- Cardiac index improved, indicating enhanced right ventricular function.
Implications:
- Aerosolized prostacyclin demonstrates potential as a selective pulmonary vasodilator in infants.
- Its favorable safety profile and ease of administration suggest it as a viable alternative to inhaled nitric oxide for IPH management.
Abstract:
Prostacyclin aerosol (100 ng/kg.min) caused selective pulmonary vasodilation without causing systemic hypotension in an infant with idiopathic pulmonary hypertension. Cardiac index increased suggesting improved right ventricular function. CONCLUSION Aerosolized prostacyclin causes selective pulmonary vasodilation and may thereby improve systemic haemodynamics in infants with primary pulmonary hypertension. Because of the lack of known toxicity and the uncomplicated mode of administration it may be a useful alternative to inhaled nitric oxide.